Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus FEMOGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus FEMOGEN.
DIETHYLSTILBESTROL vs FEMOGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
Femogen is a combination of estradiol (an estrogen) and norethindrone acetate (a progestin). Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and promoting proliferation of the endometrium. Norethindrone acetate suppresses gonadotropin secretion and inhibits endometrial proliferation, reducing the risk of endometrial hyperplasia associated with estrogen therapy.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
1 mg orally once daily for 21 days, followed by 7 days off; for HRT, 1 mg orally once daily continuously.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Terminal half-life: 13.2 ± 2.3 hours; clinically, steady-state reached after 3-5 days.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Renal: 60-70% as glucuronide conjugates; Biliary/Fecal: 30-40% as metabolites; <1% unchanged.
Category C
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."